{"id":199982,"date":"2026-03-09T07:17:25","date_gmt":"2026-03-09T06:17:25","guid":{"rendered":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/"},"modified":"2026-03-09T07:17:25","modified_gmt":"2026-03-09T06:17:25","slug":"espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2","status":"publish","type":"post","link":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/","title":{"rendered":"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg\" \/><\/p>\n<p>La <a href=\"https:\/\/www.sanidad.gob.es\/areas\/farmacia\/precios\/comisionInteministerial\/home.htm\" target=\"_blank\" rel=\"noopener\">Comisi\u00f3n <strong><\/strong>Interministerial de Precios de los Medicamentos (CIPM)<\/a> ha acordado la financiaci\u00f3n p\u00fablica de la profilaxis preexposici\u00f3n (PrEP) inyectable frente al VIH, comercializada como Apretude (cabotegravir de acci\u00f3n prolongada), convirtiendo a Espa\u00f1a en el primer pa\u00eds de la Uni\u00f3n Europea\u00a0en incluir esta innovaci\u00f3n terap\u00e9utica en la cartera de servicios de su sistema nacional de salud.<\/p>\n<p>La decisi\u00f3n adoptada en el seno del \u00f3rgano competente en materia de financiaci\u00f3n y fijaci\u00f3n de precios de medicamentos garantiza su incorporaci\u00f3n como prestaci\u00f3n farmac\u00e9utica del <a href=\"https:\/\/www.sanidad.gob.es\/organizacion\/sns\/home.htm\" target=\"_blank\" rel=\"noopener\">Sistema Nacional de Salud (SNS)<\/a>, en condiciones de equidad y acceso universal.<\/p>\n<p>Apretude est\u00e1 indicado para personas VIH negativas con alto riesgo de adquirir la infecci\u00f3n por v\u00eda sexual. Su administraci\u00f3n intramuscular cada dos meses elimina la necesidad de una toma diaria, como ocurre con la PrEP oral, facilitando la adherencia en determinados perfiles de poblaci\u00f3n.<\/p>\n<p>Los ensayos cl\u00ednicos internacionales han demostrado que el cabotegravir de acci\u00f3n prolongada ofrece una elevada eficacia en la prevenci\u00f3n de la infecci\u00f3n por VIH en comparaci\u00f3n con la pauta oral diaria en contextos donde la adherencia puede verse comprometida.<\/p>\n<p>La autorizaci\u00f3n para su comercializaci\u00f3n fue concedida por la <a href=\"https:\/\/european-union.europa.eu\/institutions-law-budget\/institutions-and-bodies\/search-all-eu-institutions-and-bodies\/european-medicines-agency-ema_es\" target=\"_blank\" rel=\"noopener\">Agencia Europea de Medicamentos (EMA)<\/a>, permitiendo su disponibilidad en los Estados miembros. Con esta decisi\u00f3n de financiaci\u00f3n p\u00fablica, Espa\u00f1a se sit\u00faa a la vanguardia europea en la incorporaci\u00f3n de innovaciones preventivas frente al VIH.<\/p>\n<p>La medida se alinea con las recomendaciones de la <a href=\"https:\/\/www.who.int\/es\" target=\"_blank\" rel=\"noopener\">Organizaci\u00f3n Mundial de la Salud<\/a> y de <a href=\"https:\/\/www.exteriores.gob.es\/RepresentacionesPermanentes\/oficinadelasnacionesunidas\/es\/Organismo\/Paginas\/Otros\/ONUSIDA.aspx\" target=\"_blank\" rel=\"noopener\">ONUSIDA<\/a>, que instan a ampliar el acceso a estrategias de prevenci\u00f3n eficaces para avanzar hacia la eliminaci\u00f3n del VIH como problema de salud p\u00fablica.<\/p>\n<p>Con esta incorporaci\u00f3n, Espa\u00f1a consolida una estrategia integral frente al VIH basada en la prevenci\u00f3n combinada, el diagn\u00f3stico precoz, el tratamiento antirretroviral y la lucha contra el estigma, avanzando de forma decidida hacia los objetivos internacionales de control y eliminaci\u00f3n de la infecci\u00f3n.<\/p>\n<p>[Fuente: <a href=\"https:\/\/www.sanidad.gob.es\/gabinete\/notasPrensa.do?id=6860\" target=\"_blank\" rel=\"noopener\">Ministerio de Sanidad<\/a>. 26\/02\/2026]<\/p>\n<p>[Foto: <a href=\"https:\/\/www.flickr.com\/photos\/niaid\/\" target=\"_blank\" rel=\"noopener\">NIAID<\/a> \/ <a href=\"https:\/\/flic.kr\/p\/2pj59uw\" target=\"_blank\" rel=\"noopener\">HIV Virus <\/a> \/ <a href=\"https:\/\/creativecommons.org\/licenses\/by\/2.0\/\" target=\"_blank\" rel=\"noopener\">CC BY 2.0<\/a>]<\/p>","protected":false},"excerpt":{"rendered":"<p>La Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM) ha acordado la financiaci\u00f3n p\u00fablica de la profilaxis preexposici\u00f3n (PrEP) inyectable frente al VIH, comercializada como Apretude (cabotegravir de acci\u00f3n prolongada), convirtiendo a Espa\u00f1a en el primer pa\u00eds de la Uni\u00f3n Europea\u00a0en incluir esta innovaci\u00f3n terap\u00e9utica en la cartera de servicios de su sistema nacional de [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-199982","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.9 (Yoast SEO v26.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH\" \/>\n<meta property=\"og:description\" content=\"La Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM) ha acordado la financiaci\u00f3n p\u00fablica de la profilaxis preexposici\u00f3n (PrEP) inyectable frente al VIH, comercializada como Apretude (cabotegravir de acci\u00f3n prolongada), convirtiendo a Espa\u00f1a en el primer pa\u00eds de la Uni\u00f3n Europea\u00a0en incluir esta innovaci\u00f3n terap\u00e9utica en la cartera de servicios de su sistema nacional de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T06:17:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH\",\"datePublished\":\"2026-03-09T06:17:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\"},\"wordCount\":375,\"publisher\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#organization\"},\"image\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\",\"url\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\",\"name\":\"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH - bip4ex\",\"isPartOf\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg\",\"datePublished\":\"2026-03-09T06:17:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage\",\"url\":\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg\",\"contentUrl\":\"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/helloproject.es\/vigilancia\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#website\",\"url\":\"https:\/\/helloproject.es\/vigilancia\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\/\/helloproject.es\/vigilancia\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png\",\"contentUrl\":\"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/","og_locale":"es_ES","og_type":"article","og_title":"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH","og_description":"La Comisi\u00f3n Interministerial de Precios de los Medicamentos (CIPM) ha acordado la financiaci\u00f3n p\u00fablica de la profilaxis preexposici\u00f3n (PrEP) inyectable frente al VIH, comercializada como Apretude (cabotegravir de acci\u00f3n prolongada), convirtiendo a Espa\u00f1a en el primer pa\u00eds de la Uni\u00f3n Europea\u00a0en incluir esta innovaci\u00f3n terap\u00e9utica en la cartera de servicios de su sistema nacional de [&hellip;]","og_url":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/","og_site_name":"bip4ex","article_published_time":"2026-03-09T06:17:25+00:00","og_image":[{"url":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg","type":"","width":"","height":""}],"author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH","datePublished":"2026-03-09T06:17:25+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/"},"wordCount":375,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg","articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/","url":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/","name":"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg","datePublished":"2026-03-09T06:17:25+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#primaryimage","url":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg","contentUrl":"https:\/\/www.infosalut.com\/images\/noticies\/cc\/cc-epr1073.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/espana-primer-pais-de-la-union-europea-en-financiar-la-prep-inyectable-frente-al-vih-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Espa\u00f1a, primer pa\u00eds de la Uni\u00f3n Europea en financiar la PrEP inyectable frente al VIH"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/199982","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=199982"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/199982\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=199982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=199982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=199982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}